When was Riboscience founded?

Riboscience was founded in 2012 and raised its 1st funding round 5 years after it was founded.

Where is Riboscience located?

Riboscience is headquartered in Sunnyvale, United States.

How many employees does Riboscience have?

As of Jun 30, 2026, the latest employee count at Riboscience is 18.

Is Riboscience a funded company?

Riboscience is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 18, 2017.

When was the latest funding round of Riboscience?

Riboscience's latest funding was a $***** Grant (prize money) round on Sep 15, 2019, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does Riboscience rank among its competitors?

Riboscience ranks 1950th amongst 3949 active competitors, of which 1341 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Riboscience?

Riboscience's top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Riboscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of ribose-based molecules to treat viral diseases and cancers. The company has developed structurally diverse, rationally designed molecular libraries that have led to the rapid identification of a series of antiviral nucleoside analogs. Their main target indications currently are hepatitis C, influenza, and respiratory syncytial virus. The company's lead candidate is a dual nucleoside therapy, RBS-1154 combined with RBS-1049, for HCV.

Key Metrics

Founded Year

2012

Location

Sunnyvale, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Sep 15, 2019, $*****

Investors

SVT Ventures & 1 more

Ranked

1950^th among 3949 active competitors

Employee Count

18 as on Jun 30, 2026

Similar Companies

Alnylam & 1567 more

View Riboscience's full profile

Riboscience has raised funding over 2 rounds. Its first funding round was on Aug 18, 2017. Its latest funding round was a Grant (prize money) round on Sep 15, 2019 for $*****. 1 investor participated in its latest round. Riboscience has 2 institutional investors.

Here is the list of recent funding rounds of Riboscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 15, 2019	7923290	Grant (prize money)	1941444	7587731	9178373	3047842
Aug 18, 2017	1117838	Grant (prize money)	3851281	2392727	7422801	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Riboscience's funding rounds and investors

The founders of Riboscience are Klaus Klumpp and Jeffrey Glenn.

Here are the details of Riboscience's key team members:

Klaus Klumpp: Co-Founder & President of Riboscience.
Jeffrey Glenn: Co-Founder of Riboscience.
Contact Info: 1 email address

View details of Riboscience's Founder profiles and Board Members

Riboscience's employee count trend

Riboscience has 18 employees as of Jun 26. Here is Riboscience's employee count trend over the years:

Uncover Riboscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Riboscience include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Riboscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
1950th	Riboscience 2012, Sunnyvale (United States), Funding Raised	Developer of ribose-based molecules to treat viral diseases and cancers	-	SVT Ventures, HHS	32/100